DB
SNOA icon

Danske Bank’s Sonoma Pharmaceuticals SNOA Stock Holding History

Danske Bank’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Hold
1
– – ﹤0.01% 1146
2025
Q4 		$4 Hold
1
– – ﹤0.01% 1515
2025
Q3 		$4 Hold
1
– – ﹤0.01% 1447
2025
Q2 		$3 Hold
1
– – ﹤0.01% 1491
2025
Q1 		$2 Hold
1
– – ﹤0.01% 1347
2024
Q4 		$3 Hold
1
– – ﹤0.01% 1370
2024
Q3 		$3 Buy
+1
New +$5 ﹤0.01% 1567

Other funds holding SNOA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Danske Bank's SNOA Position: Q1 2026 in Review

Danske Bank held its Sonoma Pharmaceuticals (SNOA) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #1146.

Danske Bank first reported a position in SNOA in Q3 2024 and has held it in 7 quarters since. The position peaked at $4 in Q4 2025. 17 funds tracked by Wall St. Rank hold SNOA as of Q1 2026.

  • Danske Bank held 1 share of Sonoma Pharmaceuticals worth $2 as of Q1 2026.
  • Danske Bank left its Sonoma Pharmaceuticals share count unchanged in Q1 2026.
  • Sonoma Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1146 holding.
  • Danske Bank first reported a position in Sonoma Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Danske Bank's Sonoma Pharmaceuticals position peaked at $4 in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.